DISTRUTTI, ELEONORA
 Distribuzione geografica
Continente #
NA - Nord America 2.074
EU - Europa 1.427
AS - Asia 688
AF - Africa 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 4.194
Nazione #
US - Stati Uniti d'America 2.069
IE - Irlanda 422
IT - Italia 325
HK - Hong Kong 200
UA - Ucraina 195
VN - Vietnam 148
SG - Singapore 145
CN - Cina 121
FR - Francia 85
SE - Svezia 78
FI - Finlandia 69
RU - Federazione Russa 68
DE - Germania 67
TR - Turchia 37
GB - Regno Unito 26
KR - Corea 22
CH - Svizzera 20
RO - Romania 18
BE - Belgio 15
NL - Olanda 11
AT - Austria 9
UZ - Uzbekistan 8
CZ - Repubblica Ceca 7
LB - Libano 5
CA - Canada 3
GR - Grecia 3
PL - Polonia 3
AL - Albania 2
CI - Costa d'Avorio 2
EU - Europa 2
JP - Giappone 2
MX - Messico 2
EE - Estonia 1
ES - Italia 1
HU - Ungheria 1
MA - Marocco 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 4.194
Città #
Chandler 569
Dublin 417
San Mateo 214
Hong Kong 200
Dong Ket 148
Perugia 119
Altamura 104
Medford 101
Princeton 100
Jacksonville 94
Singapore 88
Ann Arbor 87
Lawrence 84
Wilmington 83
Andover 62
Beijing 53
Izmir 37
Ashburn 30
Saint Petersburg 29
Des Moines 21
Seoul 21
Timisoara 18
Los Angeles 16
Boardman 15
Brussels 15
Falls Church 14
Redwood City 14
Houston 13
Redmond 12
Den Haag 11
Helsinki 11
Norwalk 11
San Paolo di Civitate 11
Woodbridge 10
Vienna 7
Brugg 6
Florence 6
Lappeenranta 6
Dearborn 5
Shanghai 5
Cambridge 4
Chicago 4
Naples 4
New York 4
Olomouc 4
Auburn Hills 3
Bologna 3
Fremont 3
Giugliano In Campania 3
Lausanne 3
Prata Di Pordenone 3
San Diego 3
Toronto 3
Abidjan 2
Cincinnati 2
Esslingen am Neckar 2
Ferrara 2
Frankfurt am Main 2
Kiev 2
London 2
Menlo Park 2
Moscow 2
Nanjing 2
Philadelphia 2
Radeberg 2
Rome 2
Seattle 2
Stroncone 2
Tokyo 2
Alameda 1
Avignon 1
Bastia umbra 1
Bisaccia 1
Boydton 1
Bratislava 1
Brno 1
Budapest 1
Castiglione del Lago 1
Catania 1
Chengdu 1
Cork 1
Cormeilles-en-Parisis 1
Deruta 1
Edinburgh 1
Foligno 1
Guangzhou 1
Gwangmyeong 1
Hanover 1
Hefei 1
Iglesias 1
Jinan 1
Landshut 1
Lexington 1
Lit 1
Ludwigshafen 1
Magdeburg 1
Mexico 1
Miami 1
Moline 1
Napoli 1
Totale 2.974
Nome #
Activation of the farnesoid-X receptor protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs in mice. 84
Anti-HIV Protease Inhibitors Interact With NSAIDs and Exacerbate Small Intestine Enteropathy Induced by NSAIDs 84
Activation of the bile acid receptor GPBAR1 protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs and aspirin in mice. 82
The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines 79
The aryl hydrocarbon receptor (AhR) mediates the counter-regulatory effects of pelargonidins in models of inflammation and metabolic dysfunctions 71
A nitro-arginine derivative of trimebutine (NO2-Arg-Trim) attenuates pain induced by colorectal distension in conscious rats. 69
Antiatherosclerotic effect of farnesoid X receptor. 68
BAR501, A SELECTIVE GPBAR1 AGONIST, PROMOTES ADIPOSE TISSUE BROWNING AND AUTOPHAGY AND IMPROVES LIPID METABOLISM AND STEATO-HEPATITIS IN MICE FEED A HIGH FAT DIET 67
Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition 66
Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation. 64
Effect of bombesin on pancreatic regeneration after subtotal distal pancreasectomy. 64
A Comprehensive Analysis of Small Heterodimer Partner (SHP) Target Genes in Hepatic Stellate Cells and the Discovery of a New Class of SHP Agonists That Reduces Liver Fibrosis 60
Dissociation of intestinal and hepatic activities of FXR and LXRα supports metabolic effects of terminal ileum interposition in rodents. 59
a Farnesoid-X-Receptor (FXR)-Glucocorticoid Receptor (GR) Cascade Regulates Intestinal Innate Immunity in Response to FXR Activation 58
Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis 57
Identification of Cysteinyl-leukotriene-receptor 1 antagonists as ligands for the bile acid receptor GPBAR1 57
Analysis of Gastric Cancer Transcriptome Allows the Identification of Histotype Specific Molecular Signatures With Prognostic Potential 57
Gut microbiota role in irritable bowel syndrome: New therapeutic strategies 54
Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice. 53
I peptidil leucotrieni regolano la secrezione di pepsinogeno e la mobilitazione del calcio nelle cellule principali isolate 53
FXR mediates a chromatin looping in the GR promoter thus promoting the resolution of colitis in rodents. 53
Sa1518 – Mechanism of Acute Liver Decompensation Caused by Obeticholic Acid in Cholestasis is Fxr Dependent 53
The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice. 52
Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatorybowel diseases and arthritis 51
241 - GPBAR1 (TGR5) is a Modulator of Liver Immunity and Reverses Liver Inflammation in a Mouse Models of Acute Hepatitis 51
DISCOVERY OF BAR704, A POTENT AND SELECTIVE FXR AGONIST, THAT PROTECTS AGAINST LIVER FIBROSIS 51
Counter-regulatory role of bile acid activated receptors in immunity andinflammation. 50
The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease. 49
Farnesoid X receptor suppresses constitutive androstane receptoractivity at the multidrug resistance protein-4 promoter. 49
Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. 49
Su1053 - Bar704, a Potent and Selective Fxr Agonist Protects Against Intestinal Fibrosis 49
Tu1546 – Gpbar1 is a Modulator of Liver Immunity and Its Agonism Reverses Acetaminophen-Induced Hepatotoxicity by Modulating Recruitment of Liver Macrophages 49
The third gas: H2S regulates perfusion pressure in both theisolated and perfused normal rat liver and in cirrhosis. 48
Genetic and Pharmacological Dissection of the Role of Spleen Tyrosine Kinase (Syk) in Intestinal Inflammation and Immune Dysfunction in Inflammatory Bowel Diseases 48
Mo2014 – Comparative Effects of Bar502, a Dual Fxr and Gpbar1 Agonist, Obeticholic Acid and Ursodeoxycholic Acid in a Rodent Model of Nash 48
Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. 47
Nitric oxide-releasing NSAIDs inhibit interleukin 1beta converting enzyme-like cysteine proteases and protect endothelial cells from appopthosis induced by TNFx 46
Inhibition of NF-κB by a PXR-dependent pathwaymediates counter-regulatory activities of rifaximin on innate immunity inintestinal epithelial cells. 45
The Pharmacology of Bile Acids and Their Receptors 45
Serum Bile Acid Levels Before and After Sleeve Gastrectomy and Their Correlation with Obesity-Related Comorbidities 45
Tu1738 - The Aryl Hydrocarbon Receptor Mediates Anti-Inflammatory Activities of Natural and Synthetic Pelargonidines in Mouse Models of Colitis 44
Bile Acids Activated Receptors Regulate innate immunity 44
The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. 43
Metabolic variability of a multispecies probiotic preparation impacts on the anti-inflammatory activity 43
The Bile Acid Receptor GPBAR1 Modulates CCL2/CCR2 Signaling at the Liver Sinusoidal/Macrophage Interface and Reverses Acetaminophen-Induced Liver Toxicity 43
The nuclear receptor FXR regulates hepatic transport and metabolism of glutamine and glutamate 42
Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH 42
The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. 42
Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interaction 41
SHP-dependent and -independent induction of peroxisomeproliferator-activated receptor-γ by the bile acid sensor farnesoid X receptorcounter-regulates the pro-inflammatory phenotype of liver myofibroblasts. 39
The methionine connection: homocysteine and hydrogen sulfide exert opposite effects on hepatic microcirculation in rats. 39
Divergent effectiveness of multispecies probiotic preparations on intestinal microbiota structure depends on metabolic properties 39
Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis 39
Bile Acids Activated Receptors in Inflammatory Bowel Disease 39
Pregnane-X-receptor mediates the anti-inflammatoryactivities of rifaximin on detoxification pathways in intestinal epithelialcells. 38
Immunomodulatory functions of FXR 38
Discovery of a Novel Multi-Strains Probiotic Formulation with Improved Efficacy toward Intestinal Inflammation 37
Bile acids and their receptors in metabolic disorders 37
Bile acid-activated receptors and the regulation of macrophages function in metabolic disorders 37
Instruction of Intestinal Microbiota by VSL#3 Reverses NASH and Accelerated Atherosclerosis Caused by Intestinal Inflammation in ApoE(-/-) Mice 36
Targeting FXR in cholestasis: hype or hope. 36
Hydrogen sulphide induces micro opioid receptor-dependent analgesia in a rodent model of visceral pain. 35
In vivo administration of ritonavir worsens intestinal damage caused by cyclooxygease inhibitors. 35
GPBAR1 (TGR5) LIGATION PROTECTS AGAINST COLITIS DEVELOPMENT BY REGULATING LEUKOCYTE TRAFFINKING AND PROMOTING A IL-10 DEPENDENT SHIFT IN THE M1/M2 PHENOTYPE 35
Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation 35
Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH) 35
The identification of farnesoid X receptor modulators as treatment options for non-alcoholic fatty liver disease 35
Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling 35
VARIABILITY IN INDUSTRIAL PRODUCTION AFFECTS PROBIOTICS ACTIVITY: IDENTIFICATION OF BATCHES OF PROBIOTIC VSL#3 THAT INCREASES INTESTINAL PERMEABILITY AND WORSENS COLITIS IN RODENTS 33
Tu1748 - Probiotics Beyond Taxonomy: Evidence that Anti-inflammatory Properties of Live Biotherapeutic Products Require Phenotypic Characterization 33
Bile Acid Signaling in Inflammatory Bowel Diseases 33
COXIBs, CINODs and H₂S-releasing NSAIDs: currentperspectives in the development of safer non steroidal anti-inflammatory drugs 32
GPBAR1 (TGR5) AGONISM REVERSES ENDOTHELIAL DYSFUNCTION AND LIVER INJURY IN A DIETETIC MODEL OF STEATOHEPATITIS 32
GPBAR1 Functions as Gatekeeper for Liver NKT Cells and provides Counterregulatory Signals in Mouse Models of Immune-Mediated Hepatitis 31
Decoding the role of the nuclear receptor SHP in regulating hepatic stellate cells and liver fibrogenesis 30
Role of Nuclear Receptors in Lipid Dysfunction and Obesity-related Diseases. 30
Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic Adenocarcinoma 29
Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH 29
The HIV matrix protein p17 induces hepatic lipid accumulation via modulation of nuclear receptor transcriptoma 29
The Bile Acid Receptor TGR5 Maintains Gastrointestinal Homeostasis and Its Activation Rescues From Gastrointestinal Injury Caused by ASA and NSAIDs 28
Modulation of intestinal microbiota by the probiotic VSL#3 resets brain gene expression and ameliorates the age-related deficit in LTP. 28
The bile acid activated receptors GPBAR1 and FXR exert antagonistic effects on autophagy 28
Chenodeoxycholic Acid: An Update on Its Therapeutic Applications 27
Special FX: Harnessing the Farnesoid-X-Receptor to Control Bile Acid Synthesis 27
Solomonsterol A, a marine pregnane-X-receptor agonist, attenuates inflammation and immune dysfunction in a mouse model of arthritis. 26
Future trends in the treatment of non-alcoholic steatohepatitis 26
Endocrine activities and adipogenic effects of bisphenol AF and its main metabolite 26
Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders 26
Farnesoid X receptor modulators 2014-present: a patent review 26
Next-Generation Sequencing Analysis of Gastric Cancer Identifies the Leukemia Inhibitory Factor Receptor as a Driving Factor in Gastric Cancer Progression and as a Predictor of Poor Prognosis 26
Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma 25
VSL#3 Resets Insulin Signaling and Protects against NASH and Atherosclerosis in a Model of Genetic Dyslipidemia and Intestinal Inflammation. 25
Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome. 24
The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation 24
GLP-1 Mediates Regulation of Colonic ACE2 Expression by the Bile Acid Receptor GPBAR1 in Inflammation 24
Modification of Intestinal Microbiota by VSL#3 Protects Against Development of Pain in the Neonatal Maternal Separation Model. a Whole Genome Array Investigation 23
Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases 23
Organoids as ex vivo culture system to investigate infection-host interaction in gastric pre-carcinogenesis 22
Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling 21
Combinatorial targeting of GPBAR1 and CYSLTR1 reveals a mechanistic role for bile acids and leukotrienes in drug induced liver injury 21
Totale 4.234
Categoria #
all - tutte 20.648
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.648


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020306 21 16 29 3 36 24 41 11 35 53 15 22
2020/2021673 8 40 26 51 208 29 36 15 45 18 36 161
2021/2022785 10 156 9 21 27 12 20 241 9 35 106 139
2022/20231.677 118 323 13 161 143 156 0 100 588 1 57 17
2023/2024647 40 76 27 15 15 4 157 45 42 29 121 76
2024/202525 25 0 0 0 0 0 0 0 0 0 0 0
Totale 4.413